To allow IL-2 to preferentially target tumor-infiltrating lymphocytes (TILs) with long half-life, we designed ProIL2 to have four domains: human IgG1, an IL-2 variant, an IL-2 receptor, and a flexible MMP-cleavable linker. Here, IL2 is linked to neoplasm.